FierceBiotech4d
'Ongoing challenges' force Pfizer to scrap oral RSV med from ReViral buyout
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
Pfizer is said to have dropped RSV candidate from pipeline
Pfizer (NYSE:PFE) has decided not to further develop sisunatovir, an antiviral targeted at respiratory syncytial virus (RSV), ...
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...
STAT9d
After a rocky debut for new RSV tools, hopes are high as a new season approaches
Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...
scrippsnews on MSN1d
Harnessing Your Health: What you need to know about COVID-19, flu, and RSV for the fall and winter
There’s about 270 different viruses that can infect humans, and in the fall and winter we're inside more where they can ...
McKnight's Long-Term Care News4d
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
clinicaltrialsarena1d
Pfizer reports positive data from prostate cancer combination therapy trial
Pfizer has announced data from the Phase III trial of TALZENNA plus XTANDI in patients with metastatic castration-resistant ...